CA3249575A1 - Pharmaceutical composition containing budesonide for the treatment of IgA nephropathy - Google Patents

Pharmaceutical composition containing budesonide for the treatment of IgA nephropathy

Info

Publication number
CA3249575A1
CA3249575A1 CA3249575A CA3249575A CA3249575A1 CA 3249575 A1 CA3249575 A1 CA 3249575A1 CA 3249575 A CA3249575 A CA 3249575A CA 3249575 A CA3249575 A CA 3249575A CA 3249575 A1 CA3249575 A1 CA 3249575A1
Authority
CA
Canada
Prior art keywords
composition
budesonide
dissolution
dissolution medium
minutes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3249575A
Other languages
English (en)
French (fr)
Inventor
Eva Kristina RIESEL
Lena Margareta PERESWETOFF-MORATH
Kari SANDVOLD
Christian Olle Andreas PEDERSEN
Original Assignee
Calliditas Therapeutics AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=85076189&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA3249575(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB2217146.6A external-priority patent/GB202217146D0/en
Priority claimed from GBGB2217150.8A external-priority patent/GB202217150D0/en
Application filed by Calliditas Therapeutics AB filed Critical Calliditas Therapeutics AB
Publication of CA3249575A1 publication Critical patent/CA3249575A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891—Coated capsules; Multilayered drug free capsule shells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA3249575A 2022-01-24 2023-01-24 Pharmaceutical composition containing budesonide for the treatment of IgA nephropathy Pending CA3249575A1 (en)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US202263302226P 2022-01-24 2022-01-24
US202263302216P 2022-01-24 2022-01-24
US63/302,216 2022-01-24
US63/302,226 2022-01-24
GBGB2217146.6A GB202217146D0 (en) 2022-11-16 2022-11-16 New pharmaceutical compositions
GB2217150.8 2022-11-16
GB2217146.6 2022-11-16
GBGB2217150.8A GB202217150D0 (en) 2022-11-16 2022-11-16 New pharmaceutical compositions
PCT/EP2023/051680 WO2023139285A1 (en) 2022-01-24 2023-01-24 Pharmaceutical composition comprising budesonide for treating iga nephropathy

Publications (1)

Publication Number Publication Date
CA3249575A1 true CA3249575A1 (en) 2023-07-27

Family

ID=85076189

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3249575A Pending CA3249575A1 (en) 2022-01-24 2023-01-24 Pharmaceutical composition containing budesonide for the treatment of IgA nephropathy

Country Status (14)

Country Link
US (10) US11896719B2 (enExample)
EP (1) EP4469060A1 (enExample)
JP (1) JP2025508321A (enExample)
KR (2) KR102919268B1 (enExample)
CN (6) CN120754111A (enExample)
AU (1) AU2023210461A1 (enExample)
CA (1) CA3249575A1 (enExample)
CL (1) CL2024002201A1 (enExample)
CO (1) CO2024009565A2 (enExample)
GE (1) GEAP202416588A (enExample)
IL (1) IL314067A (enExample)
MX (1) MX2024009024A (enExample)
TW (2) TW202547520A (enExample)
WO (1) WO2023139285A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11896719B2 (en) * 2022-01-24 2024-02-13 Calliditas Therapeutics Ab Pharmaceutical compositions
WO2026132451A1 (en) 2024-12-19 2026-06-25 Synthon B.V. Budesonide enteric capsule formulation

Family Cites Families (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4123403A (en) 1977-06-27 1978-10-31 The Dow Chemical Company Continuous process for preparing aqueous polymer microsuspensions
US4502888A (en) 1982-12-13 1985-03-05 The Dow Chemical Company Aqueous dispersions of plasticized polymer particles
US5643602A (en) * 1989-11-22 1997-07-01 Astra Aktiebolag Oral composition for the treatment of inflammatory bowel disease
SE8903914D0 (sv) 1989-11-22 1989-11-22 Draco Ab Oral composition for the treatment of inflammatory bowel diseases
US5472712A (en) * 1991-12-24 1995-12-05 Euroceltique, S.A. Controlled-release formulations coated with aqueous dispersions of ethylcellulose
PT621032E (pt) 1993-04-23 2001-01-31 Novartis Ag Dispositivo de distribuicao de libertacao controlada de farmaco
DE4332394A1 (de) 1993-09-23 1995-03-30 Falk Pharma Gmbh Budesonid-Pellets mit kontrolliertem Freigabeprofil und Verfahren zu ihrer Herstellung
US5482718A (en) * 1994-03-23 1996-01-09 Hoffmann-La Roche Inc. Colon-targeted delivery system
GB9412394D0 (en) 1994-06-21 1994-08-10 Danbiosyst Uk Colonic drug delivery composition
DE4446891A1 (de) 1994-12-27 1996-07-04 Falk Pharma Gmbh Stabile wäßrige Budesonid-Lösung
SG80553A1 (en) 1995-07-20 2001-05-22 Tanabe Seiyaku Co Pharmaceutical preparation in form of coated capsule releasable at lower part of digestive tract
GB9516268D0 (en) 1995-08-08 1995-10-11 Danbiosyst Uk Compositiion for enhanced uptake of polar drugs from the colon
GB9722426D0 (en) 1997-10-23 1997-12-24 Univ London Pharmacy Controlled release formulations
SE514128C2 (sv) * 1998-03-17 2001-01-08 Pharmalink Ab Användning av en glukokortikoid för framställning av ett läkemedel för behandling av glomerulonefrit
US6239120B1 (en) 1998-03-17 2001-05-29 Pharmalink Ab Method and means for treating glomerulonephritis
US8895064B2 (en) * 1999-06-14 2014-11-25 Cosmo Technologies Limited Controlled release and taste masking oral pharmaceutical composition
WO2000076478A1 (en) 1999-06-14 2000-12-21 Cosmo S.P.A. Controlled release and taste masking oral pharmaceutical compositions
DE10004939C1 (de) 2000-02-05 2001-08-23 Lothar Moerl Steuerbare Gasanströmeinrichtung für Strahlschichtapparate
DE10013029A1 (de) 2000-03-17 2001-09-20 Roehm Gmbh Mehrschichtige Arzneiform für die Colonfreigabe
ITRM20010614A1 (it) 2001-10-16 2003-04-16 Italchimici S P A Preparazione farmaceutica di una soluzione idro/propilenica di budesonide e suo procedimento di preparazione.
DE10162781A1 (de) 2001-12-20 2003-07-03 Glatt Ingtech Gmbh Strahlschichtapparat zur chargenweisen oder kontinuierlichen Prozessführung und Verfahren zum Betreiben eines Strahlschichtapparates
DE10214002A1 (de) 2002-03-27 2003-10-09 Roehm Gmbh Pharmazeutische Formulierung für den Wirkstoff Budesonid
DE10250543A1 (de) 2002-10-29 2004-05-19 Röhm GmbH & Co. KG Mehrschichtige Arzneiform
WO2004052607A1 (en) 2002-12-10 2004-06-24 Cps Orocel Llc Method of preparing biologically active formulations
DE10322062A1 (de) 2003-05-15 2004-12-02 Glatt Ingenieurtechnik Gmbh Verfahren und Vorrichtung zum Aufbringen von Flüssigkeiten in eine Feststoffströmung eines Strahlschichtapparates
DE10325989A1 (de) 2003-06-07 2005-01-05 Glatt Gmbh Verfahren zur Herstellung von und daraus resultierende Mikropellets sowie deren Verwendung
AR041873A1 (es) 2003-10-30 2005-06-01 Pablo Cassara Srl Lab Una formulacion farmaceutica en aerosol adecuada para la inhalacion oral o nasal que contienen glucocorticoides en solucion estable al almacenamiento; un metodo para estabilzar formulaciones y uso de un agente estabilizante
DE102004043863A1 (de) 2004-09-10 2006-03-16 Nitec Pharma Ag Tabletten mit orts- und zeitgesteuerter Wirkstofffreisetzung im Gastrointestinum
DE102005037630A1 (de) 2005-08-09 2007-02-15 Glatt Gmbh Verfahren zur Herstellung von Teilchen aus pharmazeutischen Substanzen, Teilchen aus pharmazeutischen Substanzen sowie deren Verwendung
DE102005060393A1 (de) 2005-12-16 2007-06-21 Add Advanced Drug Delivery Technologies Ltd. Orales Präparat mit kontrollierter Freisetzung
CN101108171A (zh) 2006-07-17 2008-01-23 复旦大学 一种布地奈德肠溶缓释微丸及其制备方法
EP2002835A1 (en) 2007-06-04 2008-12-17 GenKyo Tex Pyrazolo pyridine derivatives as NADPH oxidase inhibitors
US20090004281A1 (en) 2007-06-26 2009-01-01 Biovail Laboratories International S.R.L. Multiparticulate osmotic delivery system
CA2709561A1 (en) 2007-12-17 2009-06-25 Combinatorx, Incorporated Therapeutic regimens for the treatment of immunoinflammatory disorders
GB0808537D0 (en) 2008-05-12 2008-06-18 Archimedes Dev Ltd Compositions
EP2165707A1 (en) 2008-09-23 2010-03-24 Genkyo Tex Sa Pyrazolo pyridine derivatives as NADPH oxidase inhibitors
EP2166009A1 (en) 2008-09-23 2010-03-24 Genkyo Tex Sa Pyrazolo pyridine derivatives as nadph oxidase inhibitors
EP2166008A1 (en) 2008-09-23 2010-03-24 Genkyo Tex Sa Pyrazolo pyridine derivatives as NADPH oxidase inhibitors
EP2166010A1 (en) 2008-09-23 2010-03-24 Genkyo Tex Sa Pyrazolo pyridine derivatives as NADPH oxidase inhibitors
US8945616B2 (en) * 2009-02-17 2015-02-03 Mylan Pharmaceuticals Inc. Controlled release budesonide minitablets
RU2578430C2 (ru) 2009-11-03 2016-03-27 Липидор Аб Композиция, образующая липидный слой, для нанесения на поверхность живого организма
WO2012116362A2 (en) 2011-02-25 2012-08-30 The Johns Hopkins University Chalcone derivatives as nrf2 activators
AU2012251135A1 (en) 2011-05-02 2013-11-07 Lipidor Ab Treatment of psoriasis
EP2591782A1 (en) 2011-11-11 2013-05-15 Johann Wolfgang Goethe-Universität Nadph oxidase 4 inhibitors and use thereof
WO2013078261A1 (en) 2011-11-22 2013-05-30 The University Of Maryland, Baltimore Treatment of muscular conditions and muscular dystrophies
EP2857399A1 (en) 2013-10-03 2015-04-08 GenKyoTex SA Compounds useful for the treatment of PDE5 inhibitor-poorly responsive erectile dysfunction
IN2013MU03373A (enExample) 2013-10-25 2015-07-17 Cadila Healthcare Ltd
CN112006989A (zh) 2013-11-14 2020-12-01 立普妥公司 包含磷脂酰胆碱的可喷雾的局部用载体和组合物
WO2015071812A1 (en) 2013-11-18 2015-05-21 Wockhardt Limited Solid oral modified-release composition comprising budesonide or salt thereof
GB201419257D0 (en) 2014-10-29 2014-12-10 Jagotec Ag Pharmaceutical compositions
EP3034500A1 (en) 2014-12-17 2016-06-22 Genkyotex Sa Amido thiazole derivatives as NADPH oxidase inhibitors
US20190125678A1 (en) 2015-01-30 2019-05-02 Mylan, Inc. Sustained-Release Oral Dosage Forms for Low Aqueous Solubility Compounds
EP3098220A1 (en) 2015-05-28 2016-11-30 GenKyoTex SA Process for the preparation of a nadph oxidase inhibitor and its polymorphs and uses thereof
JP2018530535A (ja) 2015-09-11 2018-10-18 サン・ファーマシューティカル・インダストリーズ・リミテッド ブデゾニドの経口医薬剤形
UY36948A (es) 2015-10-13 2017-05-31 Flexion Therapeutics Inc Formulaciones de corticosteroides para mantener concentraciones de corticosteroide en el líquido sinovial
CN105663091A (zh) 2016-01-28 2016-06-15 上海信谊百路达药业有限公司 一种布地奈德肠溶缓释胶囊及其制备方法
US11590084B2 (en) 2016-05-02 2023-02-28 Roman Bielski Microcapsules for controlled delivery of an active pharmaceutical ingredient
US10286036B2 (en) 2017-05-12 2019-05-14 Aurinia Pharmaceuticals Inc. Protocol for treatment of lupus nephritis
EP3479843A1 (en) 2017-11-01 2019-05-08 GenKyoTex Suisse SA Use of nox inhibitors for treatment of cancer
JP2021515034A (ja) 2018-02-22 2021-06-17 アビオール、インコーポレイテッド 経粘膜フィルム組成物ならびにそれを作製及び使用する方法
EP3553081A1 (en) 2018-04-12 2019-10-16 Bayer Aktiengesellschaft Atrial natriuretic peptide engrafted antibodies
WO2020011938A1 (en) 2018-07-11 2020-01-16 Medizinische Universität Wien Glucocorticoids for the topical treatment of autoimmune gastritis
EP3628669A1 (en) 2018-09-28 2020-04-01 GenKyoTex Suisse SA Novel compounds as nadph oxidase inhibitors
CN110507627B (zh) 2019-09-29 2021-11-02 重庆医药高等专科学校 一种布地奈德的口服控释药物组合物
WO2021127003A1 (en) 2019-12-16 2021-06-24 Children's Medical Center Corporation Treating heart disease in muscular dystrophy patients
CN112999229B (zh) 2019-12-19 2023-01-24 江苏恒瑞医药股份有限公司 一种包含布地奈德的口服药物组合物
WO2022222972A1 (zh) 2021-04-20 2022-10-27 江苏恒瑞医药股份有限公司 用于药物特定递送的胶囊及其制备方法
CN117157079A (zh) 2021-04-20 2023-12-01 江苏恒瑞医药股份有限公司 一种口服肠溶皮质类固醇的药物组合物
CN115737597A (zh) 2021-09-02 2023-03-07 江苏豪森药业集团有限公司 一种口服的肠溶速释药物组合物、制备方法及其应用
US20240033225A1 (en) * 2022-01-24 2024-02-01 Calliditas Therapeutics Ab Pharmaceutical compositions
US11896719B2 (en) * 2022-01-24 2024-02-13 Calliditas Therapeutics Ab Pharmaceutical compositions

Also Published As

Publication number Publication date
TW202339765A (zh) 2023-10-16
MX2024009024A (es) 2024-11-08
US20250312283A1 (en) 2025-10-09
US20240173264A1 (en) 2024-05-30
CN120053463A (zh) 2025-05-30
US12311057B2 (en) 2025-05-27
GEAP202416588A (en) 2024-11-25
US20240122863A1 (en) 2024-04-18
US20250381147A1 (en) 2025-12-18
US12171882B2 (en) 2024-12-24
US20250268835A1 (en) 2025-08-28
IL314067A (en) 2024-09-01
WO2023139285A1 (en) 2023-07-27
JP2025508321A (ja) 2025-03-26
US12171883B2 (en) 2024-12-24
CO2024009565A2 (es) 2024-09-19
CN121774982A (zh) 2026-04-03
EP4469060A1 (en) 2024-12-04
AU2023210461A1 (en) 2024-07-18
US11896719B2 (en) 2024-02-13
TWI896928B (zh) 2025-09-11
US20250057775A1 (en) 2025-02-20
TW202547520A (zh) 2025-12-16
CN120754112A (zh) 2025-10-10
CN120754113A (zh) 2025-10-10
KR102919268B1 (ko) 2026-01-27
KR20240141771A (ko) 2024-09-27
KR20250008979A (ko) 2025-01-16
US20230293444A1 (en) 2023-09-21
US20250255824A1 (en) 2025-08-14
CL2024002201A1 (es) 2025-01-03
US20250312282A1 (en) 2025-10-09
US20250381146A1 (en) 2025-12-18
CN121796407A (zh) 2026-04-07
CN120754111A (zh) 2025-10-10

Similar Documents

Publication Publication Date Title
US12311057B2 (en) Pharmaceutical compositions
US20240033225A1 (en) Pharmaceutical compositions
US10864228B2 (en) Oral cholestyramine formulation and use thereof
CN110996915B (zh) 考来烯胺丸粒、口服考来烯胺制剂及其用途
US20200046758A1 (en) Oral cholestyramine formulation and use thereof
US20200046636A1 (en) Oral cholestyramine formulation and use thereof
CN118591376A (zh) 用于治疗IgA肾病的包含布地奈德的药物组合物
HK40125809A (en) Pharmaceutical composition comprising budesonide for treating iga nephropathy
HK40111255A (en) Pharmaceutical composition comprising budesonide for treating iga nephropathy
BR122026001808A2 (pt) Composições farmacêuticas que compreendem budesonida para tratar nefropatia por iga
TW201022215A (en) Compositions comprising 4-(2-(5-bromo-4-(1-cyclopropylnaphthalen-4-yl)-4H-1,2,4-triazol-3-ylthio)acetamido)-3-chlorobenzoic acid and pharmaceutically acceptable salts thereof, and methods for preparing and using same
HK40001801B (en) Oral cholestyramine formulation and use thereof

Legal Events

Date Code Title Description
A00 Application filed

Free format text: ST27 STATUS EVENT CODE: A-0-1-A10-A00-A101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION RECEIVED - PCT

Effective date: 20240723

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD

Year of fee payment: 2

A00 Application filed

Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A00-A102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: COMPLIANCE REQUIREMENTS DETERMINED MET

Effective date: 20250103

A15 Pct application entered into the national or regional phase

Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A15-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: NATIONAL ENTRY REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20250103

P18 Priority claim added or amended

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P18-P105 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRIORITY CLAIM REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20250103

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250214

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST TO REGISTER A DOCUMENT RECEIVED

Effective date: 20250220

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W200 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST OR RESPONSE SUBMITTED ONLINE

Effective date: 20250220

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250220

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W200 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST OR RESPONSE SUBMITTED ONLINE

Effective date: 20250303

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD

Year of fee payment: 3

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20251218

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20251218

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REGISTER A DOCUMENT REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20260513

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260601